MA26702A1 - Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation - Google Patents

Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation

Info

Publication number
MA26702A1
MA26702A1 MA25827A MA25827A MA26702A1 MA 26702 A1 MA26702 A1 MA 26702A1 MA 25827 A MA25827 A MA 25827A MA 25827 A MA25827 A MA 25827A MA 26702 A1 MA26702 A1 MA 26702A1
Authority
MA
Morocco
Prior art keywords
migraine
treatment
preparation
pharmaceutical compositions
metoclopramide
Prior art date
Application number
MA25827A
Other languages
English (en)
Inventor
Harry Sands Georges
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26702A1 publication Critical patent/MA26702A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

métoclopramide sont associés dans l'organisme d'un mammifère souffrant de migraine. 15. Procédé pour la production d'une composition pharmaceutique destinée au traitement de la migraine suivant les revendications 12 et 14, caractérisé en ce qu'il comprend l'association d'élétriptan, de métoclopramide et d'un support pharmaceutiquement acceptable. Compositions pharmaceutiques pour le traitement de la migraine, et procédé pour leur préparation La présente invention concerne une composition pharmaceutique comprenant du métoclopramide, un agoniste des récepteurs 5HT1 et un support pharmaceutiquement acceptable. Elle concerne également un procédé pour sa préparation. Application : utilisation de cette composition pharmaceutique pour le traitement de la migraine chez un mammifère.
MA25827A 1998-10-30 1999-10-27 Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation MA26702A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10632898P 1998-10-30 1998-10-30

Publications (1)

Publication Number Publication Date
MA26702A1 true MA26702A1 (fr) 2004-12-20

Family

ID=22310818

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25827A MA26702A1 (fr) 1998-10-30 1999-10-27 Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation

Country Status (34)

Country Link
US (2) US6255334B1 (fr)
EP (1) EP1126840A1 (fr)
JP (1) JP2002528497A (fr)
KR (1) KR20010089363A (fr)
CN (1) CN1325304A (fr)
AP (1) AP2001002129A0 (fr)
AR (1) AR019246A1 (fr)
AU (1) AU5994799A (fr)
BG (1) BG105534A (fr)
BR (1) BR9914901A (fr)
CA (1) CA2348543A1 (fr)
CO (1) CO4950530A1 (fr)
CZ (1) CZ20011468A3 (fr)
EA (1) EA200100284A1 (fr)
EE (1) EE200100243A (fr)
GT (1) GT199900189A (fr)
HK (1) HK1040929A1 (fr)
HR (1) HRP20010298A2 (fr)
HU (1) HUP0104696A3 (fr)
ID (1) ID28291A (fr)
IL (1) IL141957A0 (fr)
IS (1) IS5898A (fr)
MA (1) MA26702A1 (fr)
NO (1) NO20012013L (fr)
OA (1) OA11669A (fr)
PA (1) PA8484801A1 (fr)
PE (1) PE20001284A1 (fr)
PL (1) PL347541A1 (fr)
SK (1) SK5522001A3 (fr)
TN (1) TNSN99203A1 (fr)
TR (1) TR200101174T2 (fr)
TW (1) TW524692B (fr)
WO (1) WO2000025778A1 (fr)
ZA (1) ZA200103322B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0105131D0 (en) * 2001-03-01 2001-04-18 Pfizer Ltd Compositions having improved bioavailability
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
NZ529417A (en) * 2001-05-24 2006-11-30 Alexza Pharmaceuticals Inc Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
WO2002094242A1 (fr) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Administration de rizatriptan ou de zolmitriptan par voie d'inhalation
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
WO2003041693A1 (fr) * 2001-11-09 2003-05-22 Alexza Molecular Delivery Corporation Administration de diazepam a travers une voie pulmonaire
AU2002363947A1 (en) 2001-11-21 2003-07-24 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
EP1503744A1 (fr) 2002-05-13 2005-02-09 Alexza Molecular Delivery Corporation Distribution de medicament a base d'amines par voie d'inhalation
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
CA2507159A1 (fr) 2002-11-26 2004-06-10 Alexza Molecular Delivery Corporation Utilisation de loxapine et de amoxapine pour la fabrication d'un analgesique
US7550133B2 (en) 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
CA2526478A1 (fr) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Procede de regulation thermique uniforme d'un substrat ; unite de chauffage integree et unite d'administration de medicaments recourant a ce procede
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US20060002989A1 (en) * 2004-06-10 2006-01-05 Ahmed Salah U Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
JP5833804B2 (ja) * 2005-04-13 2015-12-16 ニューラクソン，インコーポレーテッド Ｎｏｓ阻害活性を有する置換インドール化合物
WO2007118314A1 (fr) * 2006-04-13 2007-10-25 Neuraxon, Inc. Indoles 1,5- et 3,6-substitués à activité inhibitrice vis-à-vis de nos
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
EP2121088B1 (fr) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Unité chauffante à utiliser dans un dispositif d'administration de médicament
US20090131503A1 (en) * 2007-11-16 2009-05-21 Annedi Subhash C 3,5 - substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
EP2220075A4 (fr) * 2007-11-16 2012-02-29 Neuraxon Inc Composés d'indole et procédés de traitement de la douleur viscérale
AU2008321353A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
AU2013202680C1 (en) * 2008-04-28 2016-06-23 Zogenix, Inc. Novel formulations for treatment of migraine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
EP1024833A1 (fr) * 1996-07-11 2000-08-09 Farmarc Nederland B.V. Composition pharmaceutique contenant un sel d'addition acide d'un medicament de base
GB9709739D0 (en) 1997-05-14 1997-07-02 Merck Sharp & Dohme Pharmaceutical formulation

Also Published As

Publication number Publication date
BG105534A (en) 2001-12-29
US6255334B1 (en) 2001-07-03
TR200101174T2 (tr) 2001-10-22
EA200100284A1 (ru) 2001-10-22
PL347541A1 (en) 2002-04-08
EE200100243A (et) 2002-12-16
US20010020036A1 (en) 2001-09-06
HRP20010298A2 (en) 2002-06-30
IL141957A0 (en) 2002-03-10
ID28291A (id) 2001-05-10
AR019246A1 (es) 2001-12-26
KR20010089363A (ko) 2001-10-06
HK1040929A1 (zh) 2002-06-28
ZA200103322B (en) 2002-06-10
IS5898A (is) 2001-03-16
EP1126840A1 (fr) 2001-08-29
PA8484801A1 (es) 2000-09-29
HUP0104696A3 (en) 2003-05-28
WO2000025778A1 (fr) 2000-05-11
NO20012013D0 (no) 2001-04-24
OA11669A (en) 2005-01-05
PE20001284A1 (es) 2000-11-22
CO4950530A1 (es) 2000-09-01
CN1325304A (zh) 2001-12-05
SK5522001A3 (en) 2002-05-09
AU5994799A (en) 2000-05-22
TW524692B (en) 2003-03-21
AP2001002129A0 (en) 2001-06-30
CZ20011468A3 (cs) 2002-04-17
NO20012013L (no) 2001-04-24
HUP0104696A2 (hu) 2002-05-29
GT199900189A (es) 2001-04-21
BR9914901A (pt) 2001-07-17
JP2002528497A (ja) 2002-09-03
CA2348543A1 (fr) 2000-05-11
TNSN99203A1 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
MA26702A1 (fr) Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation
TNSN01068A1 (fr) Compositions pharmaceutiques pour le traitement de maladies comportant un dysfonctionnement cognitif
DZ2639A1 (fr) Composés thérapeutiquement actifs basés sur le remplacement bio-isostérique du catéchol par l'indazole dans des inhibiteurs de PDE4 leur procédé de production et compositions pharmaceutiques les contenant.
TNSN99039A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
MX9606546A (es) Compuestos inhibidores de la enzima conversiva de interleukina-1 beta.
TNSN97040A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.
EA200100872A1 (ru) Композиция валдекоксиба
MA26536A1 (fr) Association de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation.
DZ2303A1 (fr) Dérivés d'indazole nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
CA2330500A1 (fr) Compositions pharmaceutiques gelifiables
TNSN01173A1 (fr) Compositions pharmaceutiques comprenant un antagoniste des recepteurs de nmda.
NZ509762A (en) 5-Azatricyclo[3.3.1.1<3,7>]decane derivatives, pharmaceuticals thereof, and their use as cholinergic receptor agonists and antagonists
MA26732A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation
MA26741A1 (fr) Suspensions de ziprasidone nouvelles et procede pour leur preparation.
DZ2948A1 (fr) Dérivé d'indole nouveau, procédé pour sa préparation et compositions pharmaceutiques le contenant.
MA24704A1 (fr) Formulations nouvelles de paroxetine et procede pour leur preparation
CA2377519A1 (fr) Compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau
GB2266665B (en) 5-HT1-like receptor agonist for rectal administration
EA200400302A1 (ru) Способ лечения первичной бессонницы
DZ2954A1 (fr) Antagoniste des recepteurs de vitronectine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
MA27690A1 (fr) Composition pharmaceutique androgene et procede pour le traitement de la depression.
MA24682A1 (fr) Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant
TNSN00142A1 (fr) Complexe d'eletriptan et d'une sulfobutylether- betacyclodextrine, procede pour sa preparation et compositions pharmaceutiques les contenant.
TNSN98124A1 (fr) Compositions de sertraline solubilisee